Augean (AUG LN) Board changes and reduction in expectations | First Derivatives (FDP LN) Agreement with European Space Agency | Futura Medical (FUM LN) Market research supports the commercial potential of Eroxon® | Low & Bonar (LWB LN) Civil Engineering struggling | Sinclair Pharma (SPH LN) Forecast update; profitability inflection and strong growth ahead
16 Oct 2017
N+1 Singer - Morning Song 16-10-2017
Sinclair Pharma (SPH:LON), 0 | Low & Bonar (LWB:LON), 0 | Futura Medical plc (FUM:LON), 39.1 | FD Technologies PLC (FDP:LON), 1,190
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Morning Song 16-10-2017
Sinclair Pharma (SPH:LON), 0 | Low & Bonar (LWB:LON), 0 | Futura Medical plc (FUM:LON), 39.1 | FD Technologies PLC (FDP:LON), 1,190
- Published:
16 Oct 2017 -
Author:
N+1 Singer Team -
Pages:
12
Augean (AUG LN) Board changes and reduction in expectations | First Derivatives (FDP LN) Agreement with European Space Agency | Futura Medical (FUM LN) Market research supports the commercial potential of Eroxon® | Low & Bonar (LWB LN) Civil Engineering struggling | Sinclair Pharma (SPH LN) Forecast update; profitability inflection and strong growth ahead